PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome – Randomized, 12-Month, Pivotal Trial Evaluating the Safety and Efficacy of Patidegib Topical Gel to Reduce the Disease Burden of Chronic BCCs in Patients with Rare Form of Skin Cancer – April 01, 2019 08:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS […]
Thank you for your interest in participating in the Phase III Patidegib 2% topical gel clinical trial for the reduction of disease burden of basal cell carcinomas in Gorlin Syndrome sponsored by PellePharm. The participating sites in the US are listed below and is divided into three categories based upon their current status of enrollment. […]
Patient recruitment is starting for Pellepharm’s Phase III Patidegib Topical Gel 2%. The BCCNS Alliance is working closely with Pellepharm and maintains the most up-to-date list of clinical sites. Click here for more information about the trial and site locations.
News Alert – Review the Patidegib 2% Topical Gel Clinical Trial Posting Pellepharm’s Phase III Clinical Trial for Patidegib Topical Gel 2% just posted to ClinicalTrials.gov Patient recruitment for Pellepharm’s Phase 3 Patidegeb Topical Gel 2% is not currently active since the site locations cannot be published until contracts are signed and official. The BCCNS […]
“Fear of failure seems to be larger than the fear of fatigue.” My parents knew a few things at the beginning of my life. That sports were not exactly my strong suit and that I was born with Basal Cell Carcinoma Nevus Syndrome (BCCNS). The two, in my opinion, have been conquered together. Although I knew […]